Posaconazole Treatment in Korea: Single-Center Experience Over 5 Years

Hyo-Jin Lee,1 Jae-Cheol Kwon,2 Si-Hyun Kim,3 Su-Mi Choi,1 Dong-Gun Lee,1,4 Sun-Hee Park,1 Jung-Hyun Choi,1 Jin-Hong Yoo,1 Byung-Sik Cho,4 Seok Lee,4 Hee-Je Kim,4 Chang-Ki Min,4 Jong-Wook Lee,4 and Woo-Sung Min4

1Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul; 2Division of Infectious Diseases, Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital, Goyang; 3Department of Life Sciences, Pohang University of Science and Technology, Pohang; 4Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Received: October 8, 2012
Revised: November 14, 2012
Accepted: November 14, 2012
Corresponding author: Dr. Dong-Gun Lee, Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea. Tel: 82-2-2258-6003, Fax: 82-2-535-2494 E-mail: symonlee@catholic.ac.kr

This study was presented in part as a poster presentation at the 2012 annual spring conference of the Korean Society for Chemotherapy and Korean Society of Infectious Diseases.

- The authors have no financial conflicts of interest.

INTRODUCTION

Posaconazole (Noxafil®), Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA) is a second-generation triazole that exhibits in vitro activity against many filamentous fungi and yeasts.1 It exerts its effects by direct inhibition of the enzyme...
lanosterol 14-α demethylase, which is responsible for the development of ergosterol.\(^2\) Posaconazole is highly lipophilic, orally absorbed, and distributed extensively in tissues.\(^3\) It has been approved by Korea Food and Drug Administration for antifungal prophylaxis in high risk patients with acute myeloid leukemia or myelodysplastic syndrome, who are expected to have prolonged neutropenia after cytotoxic chemotherapy, and in immunosuppressed patients with graft-versus-host disease after hematopoietic stem cell transplant. Also, it has received approval from US Food and Drug Administration or European Commission, for treatment of oropharyngeal candidiasis patients who require systemic administration of an antifungal agent, as well as for treatment invasive aspergillosis (IA) patients who have refractory diseases to amphotericin B deoxycholate (AMB) or itraconazole, or who are intolerant to these drugs. Posaconazole has also been proposed as an alternative therapeutic agent for infections caused by some filamentous fungi, including Mucorales.\(^4,5\) However, in Korea, there is a lack of data to support a significant role for posaconazole in the treatment of invasive fungal infection (IFI). Until recently, posaconazole was available through the Korean Orphan Drug Center. Here, we describe the use of posaconazole for the salvage treatment of patients with IFI at a single-center in Korea.

MATERIALS AND METHODS

Study design
Data from patients who received posaconazole at Catholic Blood and Marrow Transplantation Center between January 1, 2007 and September 15, 2012 were retrospectively reviewed. Information from case notes, radiological findings and laboratory results were compiled using a structured case-report form. The endpoint of the study was set to September 15, 2012 or time of death or loss to follow-up. This study was approved by the Institutional Review Board of Seoul St. Mary’s hospital at the Catholic University of Korea (No. KC12RISI0411).

Definitions
The classification of proven, probable, and possible IFI was made based on the European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria.\(^6\)

Posaconazole salvage treatment was applied when cases fulfilled at least one of the following criteria: 1) presence of a refractory IFI (disease progression, or failure to improve clinically after at least 7-day use of other licensed antifungal agents); 2) history of intolerance of standard antifungal therapy due to toxicity; 3) preexisting organ dysfunction that prevented the administration of other licensed antifungal therapies; or 4) need for long-term maintenance treatment of IFI with posaconazole after treatment with any other antifungal agent.\(^1\)

Clinical responses were evaluated at the end of treatment using both clinical and radiological data. However, if posaconazole was administered to the subject after the end of the research period, clinical responses were assessed in September 15, 2012, the end of this study. Assessments of IFI treatment responses were made based on EORTC/MSG criteria.\(^7\) Successful response were defined as either a complete response (CR) or partial response (PR).\(^8\)

Neutropenia was defined as an absolute neutrophil count <500 cells/mm\(^3\) or expected to be <500 cells/mm\(^3\) within 2-3 days.\(^9\) Toxicity was recorded and categorized using the National Cancer Institute Common Toxicity Criteria, version 4.0 when possible.\(^10\)

RESULTS

Patient characteristics
A total of 11 patients (3 males and 8 females) received posaconazole treatment between January 1, 2007 and September 15, 2012. The characteristics of the patients are shown in Table 1. The median age of the patients was 52 years. All patients had hematologic diseases. Most patients [seven (64%) of eleven] had neutropenia at the diagnosis of IFI. Five of the 11 patients received posaconazole treatment for mucormycosis, two for IA, and four for unspecified IFI for which galactomannan (GM) assays were negative. The six patients had proven, two had probable, and three had possible IFI categories. The most common site of infection was the lungs, which was documented in 6 cases (55%).

Prior antifungal drug exposure and surgical treatment
Antifungal agents administered prior to initiation of posaconazole therapy included either AMB, liposomal amphotericin B deoxycholate (LAMB), caspofungin (CSFG), or voriconazole (Table 2). Surgical resection was performed in six patients. Among them, five patients had mucormycosis and one patient (No. 9) had IA at the paranasal sinus and eye which was distinguished between mucormycosis and aspergillosis.
| Patient | Age/sex | Underlying disease (disease status) | Neutropenia at IFI diagnosis | Site of infection | Pathology, culture | Suggestive organism | Diagnosis (EORTC/MSG criteria) | GM assay |
|---------|---------|------------------------------------|----------------------------|------------------|------------------|-------------------|-------------------------|----------|
| 1       | 35/F    | AML (after reinduction CTx)        | Y                          | Fallopian tube    | Fallopian tube, colon biopsy: wide angled branched, non septated fungal hyphae | Mucormycosis | Mucormycosis (proven) | Negative |
| 2       | 52/M    | MM (during PBSC mobilization)      | N                          | Skull base        | Ear abscess culture: *Mucor* genus Mastoid biopsy: wide angled branched, non septated fungal hyphae | Mucormycosis | Mucormycosis (proven) | Negative |
| 3       | 55/M    | AML (during consolidation CTx)     | Y                          | Paranasal sinus  | Paranasal sinus biopsy: septated fungal hyphae | Miscellaneous | IFI (proven) | Negative |
| 4       | 66/F    | MPAL (during reinduction CTx)      | Y                          | Lung CNS          | Not done          | Miscellaneous | IFI (possible) | Negative |
| 5       | 47/F    | AML (during reinduction CTx)       | Y                          | Lung              | Not done          | Miscellaneous | IFI (possible) | Negative |
| 6       | 47/F    | SAA (post state of allogeneic SCT) | N                          | Lung              | Bronchial wash fluid culture: *Cunninghamella bertholletiae* Lung abscess biopsy: sporangiophores in terminal swellings fungal hyphae | Mucormycosis | Mucormycosis (proven) | Negative |
| 7       | 53/F    | AML (during reinduction CTx)       | Y                          | Lung              | Not done          | Miscellaneous | IFI (possible) | Negative |
| 8       | 37/F    | AML (after consolidation CTx)      | N                          | Lung              | Lung biopsy: wide angled branched, non septated fungal hyphae | Mucormycosis | Mucormycosis (probable) | Negative |
| 9       | 56/F    | ALL (during induction CTx)         | Y                          | Eye Paranasal sinus | Paranasal sinus biopsy: acute angled branched, septated fungal hyphae | Aspergillosis | IA (proven) | Positive |
| 10      | 32/F    | AML (after autologus SCT, recur)   | Y                          | Liver Ileum       | Liver, ileum biopsy: wide angled branched, non septated fungal hyphae | Mucormycosis | Mucormycosis (proven) | Negative |
| 11      | 67/M    | AML (after consolidation CTx)      | N                          | Lung              | Not done          | Aspergillosis | IPA (probable) | Positive |

IFI, invasive fungal infection; EORTC/MSG, the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; GM, galactomannan assay; AML, acute myeloid leukemia; CTx, chemotherapy; MM, multiple myeloma; PBSC, peripheral blood stem cell; MPAL, mixed phenotype acute leukemia; CNS, central nervous system; SAA, severe aplastic anemia; SCT, stem cell transplantation; ALL, acute lymphoblastic leukemia; IA, invasive aspergillosis; IPA, invasive pulmonary aspergillosis.
Posaconazole treatment and outcome

Posaconazole was administered for an average of 75 days (range, 4-250 days) (Table 2). The median duration of treatment was 37 days. Of the 11 patients, three met the criteria for infection refractory to other licensed antifungal therapy and two had demonstrated intolerance to standard therapy. Six required long-term maintenance therapy of IFI in which mucormycosis could not be ruled out. The overall successful response rate to posaconazole was 55% (6 of 11 patients). CR was seen in patient No. 2, who had cerebral mucormycosis. Five of the 11 patients died during the study period. However, only one death was attributed to the progression of IFI.

Safety

Two subjects developed hepatotoxicity (grades II and III), but the clinical pictures were reversed without discontinuation of posaconazole. Anorexia (grade I) and nausea (grade II) were considered possibly related to the drug. All adverse events were mild to moderate in severity. None of the patients discontinued use due to clinical or laboratory adverse events. There was no visual disturbance or QT prolongation. In general, posaconazole appeared to be safe and well tolerated in this study group.

Selected case reports

Patient No. 5

A 47-year-old woman with acute myeloid leukemia developed fever and chills after the reinduction of chemotherapy. Twelve days after the initiation of chemotherapy, she was started on cefepime and isepamicin for neutropenic fever. However, the fever persisted in spite of the administration of broad-spectrum antibiotics. Chest computed tomography

| Table 2. Antifungal Treatments and Outcomes |
|---------------------------------------------|
| Patient | Prior antifungal therapy | Surgical resection | Reason for use | Posaconazole | Adverse event (grade) | Response | Death (cause of death) |
|---------|--------------------------|-------------------|----------------|--------------|----------------------|----------|-----------------------|
| 1       | AMB 1 mg/kg/D QD (65)    | Y                 | Intolerance    | 800 10 Nausea (II) | SR               | Dead (bacterial pneumonia) |
| 2       | AMB 1 mg/kg/D QD (4)     | Y                 | Refractoriness (combination Tx with LAMB) | 800 250 Hepatotoxicity (III) | CR | Alive                |
| 3       | LAMB 3 mg/kg/D QD (37)   | N                 | Maintenance    | 800 29 Anorexia (I) | SR | Alive                |
| 4       | AMB 1 mg/kg/D QD (24)    | N                 | Intolerance    | 800 4 None | PD | Dead (fungal brain abscess) |
| 5       | AMB 1 mg/kg/D QD (3)     | N                 | Maintenance    | 600 217 Hepatotoxicity (II) | PR | Alive                |
| 6       | AMB 1 mg/kg/D QD (21)    | Y                 | Refractoriness | 800 137 None | PR | Alive                |
| 7       | AMB 1 mg/kg/D QD (15)    | N                 | Maintenance    | 600 20 None | SR | Dead (progression of AML) |
| 8       | AMB 1 mg/kg/D QD (15)    | Y                 | Maintenance    | 800 12 None | SR | Alive                |
| 9       | AMB 1 mg/kg/D QD (29)    | Y                 | Maintenance    | 800 38 None | PR | Dead (progression of ALL) |
| 10      | AMB 1 mg/kg/D QD (22)    | Y                 | Maintenance    | 800 37 None | PR | Alive                |
| 11      | AMB 1 mg/kg/D QD (3)     | N                 | Refractoriness | 800 71 None | PR | Dead (bacterial infection septic shock) |

AMB, amphotericin B deoxycholate; QD, every day; LAMB, liposomal amphotericin B deoxycholate; SR, stable response; CR, complete response; CSFG, caspofungin; PD, progression of fungal disease; PR, partial response; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; VCZ, voriconazole; BID, twice a day.
(CT) revealed multiple consolidations with surrounding ground-glass opacities in the right-upper lobe (Fig. 1A). AMB was administered empirically for fungal pneumonia. Three days after starting AMB, she began to experience severe chills, nausea, and headache upon AMB administration. AMB was substituted with CSFG, but 10 days later both the chest CT and clinical status had worsened (Fig. 1B). Instead of CSFG, LAMB therapy was started. On the eighth day of LAMB treatment, follow-up chest CT showed a slight interval decrease in consolidations, and the patient’s condition had improved. GM assays were consistently negative, therefore, the patient had the possibility of mucormycosis. Long-term LAMB therapy was required for complete resolution, but the patient wished to be discharged. Therefore, posaconazole was administered for continued treatment of IFI in the outpatient clinic. After 40 days of posaconazole treatment, the patient underwent successful allogeneic stem cell transplantation. Following the initiation of posaconazole, liver enzymes were slightly elevated, but returned to normal without discontinuation of posaconazole. The patient continues to take posaconazole and her IFI has shown a PR, as revealed by 6-month follow-up chest CT (Fig. 1C).

Patient No. 6
A 47-year-old woman was admitted to the hospital because of cough, sputum, and fever. Allogeneic stem cell transplantation for severe aplastic anemia was performed 1 month previously. Chest CT revealed necrotizing pneumonia with abscesses in the right peribronchial area and subpleural portion of the right lower lobe (RLL) (Fig. 2A and B). Serum GM assay was negative. AMB was administered in addition to meropenem. After 21 days, AMB was changed to LAMB to increase treatment efficiency. Bronchoscopic biopsy of the lung tissue showed sporangiophores in terminal swellings with positive Gomori methenamine-silver and periodic acid-Schiff stains. Cultures from bronchial-wash fluid were positive for Cunninghamella bertholletiae. Follow-up chest CT revealed little interval change in pneumonia. After 10 days, LAMB was discontinued and posaconazole was started for the treatment of refractory IFI. After posaconazole administration, her clinical status improved. About six months later, chest imaging (Fig. 2C) showed a PR in the right peribronchial region. However, abscess in the subpleural portion of the RLL remained with little interval decrease. The patient subsequently underwent a video-assisted thoracoscopic wedge resection of the RLL abscess. The pathologic results of the RLL lung abscess were consistent with Cunninghamella bertholletiae. Posaconazole was discontinued after the resection, and the patient showed no relapse.

DISCUSSION

Posaconazole has been proposed as an option for salvage treatment of IFI. Because posaconazole is not readily available in Korea, there are few clinical reports of its use.11,12

![Fig. 1. The chest computed tomography of patient No. 5 shows two, round consolidations with surrounding ground-glass opacities in the right upper lobe: (A) at the time of diagnosis of fungal pneumonia, (B) 2 weeks later, (C) 6 months later.](image1)

![Fig. 2. The chest computed tomography of patient No. 6 shows necrotizing pneumonia: (A) superior segment of the right lower lobe at the time of diagnosis of pulmonary mucormycosis, (B) subpleural portion of the right lower lobe at the time of diagnosis of pulmonary mucormycosis, (C) 6 months later.](image2)
Here, we present our experience with posaconazole as an IFI salvage treatment.

In this study, a total of 11 patients received posaconazole over the last 5 years; among them, five (45%) exhibited mucormycosis. In the rest of the subjects, however, among whom GM assays were negative in 4 IFI patients, mucormycosis could not be ruled out. It is well-known that only AMB formulations and posaconazole have shown activity against Mucorales. Although AMB formulations have been recommended as first-line therapies for mucormycosis treatment, posaconazole has been shown to be effective as a salvage therapy of refractory mucormycosis. Posaconazole may represent an alternative option for patients intolerant of AMB formulations. Among the subjects of the present study, two received posaconazole due to AMB and LAMB intolerance. Two cases received posaconazole for treatment-refractory mucormycosis. Cornely, et al. suggested that if impaired kidney function is overt or expected, posaconazole could be a reasonable option for the primary treatment of mucormycosis. However, it should be noted that posaconazole has a lower efficacy than AMB against some Mucorales species, as suggested by an in vitro study. In our study, posaconazole was used only for salvage treatment.

Posaconazole can be also applied for refractory IA. Previously, an externally controlled trial was conducted to determine the efficacy and safety of posaconazole salvage treatment in patients with IA. The overall success rate was 42% in posaconazole recipients and 26% in controls. Our study comprised one refractory invasive pulmonary aspergillosis patient who received posaconazole treatment, after the use of AMB, CSFG and voriconazole. The outcome of posaconazole for the patient was PR. Voriconazole has been recommended as a first-line treatment for IA; however, posaconazole may be an attractive option for salvage therapy of IA.

The efficacy of posaconazole salvage therapy in 91 cases of mucormycosis infection was examined retrospectively. The rate of success (CR and PR) was 60%, and 21% of the patients had stable response. In our report, the overall success rate was 55%, and only one death was attributed to IFI. Furthermore, CR was seen in a patient with lethal cerebral mucormycosis. Thus, posaconazole may be an effective modality for salvage therapy of IFI, especially mucormycosis.

In this study, 6 patients received posaconazole as maintenance therapy after using an intravenous antifungal agent. Krishnan-Natesan, et al. examined the fungicidal activity of AMB and posaconazole against Mucorales in vitro. They reported that the fungicidal activity of AMB was more rapid than that of posaconazole. The authors pointed out that using AMB in the early phase, followed by a later switch to posaconazole, may have had a clinical benefit. The findings of our study are consistent with Kontoyiannis’ strategy. The author suggested AMB use (with or without an echinocandin) for the first 2-3 weeks in patients with mucormycosis as an induction therapy, and a subsequent step-down to oral posaconazole as maintenance/secondary prophylaxis. This is a useful clinical modality because few drugs are effective against mucormycosis. In addition, no oral drug is currently available for mucormycosis outpatients. Posaconazole may thus facilitate a reduction in the hospitalization period.

In terms of safety, 11 patients had no evidence of nephrotoxicity after using posaconazole. Thus, posaconazole can be safely given to patients who are intolerant to AMB because of nephrotoxicity. The most common side effects of posaconazole are gastrointestinal disturbances [nausea (5%), vomiting (4%), and diarrhea (3%)]. The safety of posaconazole was previously examined, and treatment-related adverse effects were reported in 38%. The authors concluded that long-term posaconazole treatment is associated with a generally favorable safety profile. In our study, three patients (No. 2, 5, and 6) received posaconazole treatment for more than 3 months. Although two patients (No. 2 and 5) had hepatotoxicity and nausea, these adverse events were transient and did not warrant withholding of the medication.

To our knowledge, our results are the first report of the current status of posaconazole treatment in Korea. There were two case reports of posaconazole treatment in rhinocerebral mucormycosis in 2010. Our findings suggest that posaconazole is an effective and safe oral antifungal agent for salvage treatment of IFI, particularly when mucormycosis is diagnosed or when it cannot be ruled out due to a negative GM result. Limitations of this study include its retrospective design and use of a small sample size from a single-center. In addition, we were unable to obtain information regarding serum levels of the drug.

Further investigations should evaluate posaconazole treatment in Koreans, including its role in the prevention of IFIs and its pharmacokinetic properties.

REFERENCES

1. Mullane K, Toor AA, Kalnicky C, Rodriguez T, Klein J, Stiff P. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis 2007;9:89-96.
2. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008;42:1429-38.
3. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006;50:126-33.
4. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-7.
5. Morris MI. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 2009;66:225-36.
6. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;47:1813-21.
7. Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008;47:674-83.
8. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006;42:1398-403.
9. Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 2011;26:220-52.
10. Common terminology criteria for adverse events (CTCAE) v4.0. National Cancer Institute; 2009.
11. Yoon YK, Kim MJ, Chung YG, Shin IY. Successful treatment of a case with rhino-orbital-cerebral mucormycosis by the combination of neurosurgical intervention and the sequential use of amphotericin B and posaconazole. J Korean Neurosurg Soc 2010;47:74-7.
12. Kim WJ, Han SY, Nam YH, Kim JM, Ahn HB, Kim SJ, et al. A case of successful posaconazole salvage therapy for rhinocerebral mucormycosis after failure of amphotericin B. Korean J Med 2010;79:587-91.
13. Alastruey-Izquierdo A, Castelli MV, Cuesta I, Zaragoza O, Monzón A, Mellado E, et al. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect 2009;15 Suppl 5:71-6.
14. Cornely OA, Vehreschild JJ, Rüping MJ. Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect 2009;15 Suppl 5:77-81.
15. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007;51:2587-90.
16. Raad II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008;22:496-503.
17. Traumüller F, Popovic M, Konz KH, Smolle-Jüttner FM, Joukhadar C. Efficacy and safety of current drug therapies for invasive aspergillosis. Pharmacology 2011;88:213-24.
18. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12.
19. Greer ND. Posaconazole (Noxafil): a new triazole antifungal agent. Proc (Bayl Univ Med Cent) 2007;20:188-96.
20. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:12-5.
21. Krishnan-Natesan S, Manavathu EK, Alangaden GJ, Chandrasekar PH. A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro. Diagn Microbiol Infect Dis 2009;63:361-4.
22. Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med 2012;125(1 Suppl):S25-38.
23. Bhattacharya M, Rajeshwari K, Dhinra B. Posaconazole. J Postgrad Med 2010;56:163-7.
24. Raad II, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726-34.